Aldose reductase in diabetic microvascular complications

Area of Science:

• Biochemistry
• Endocrinology
• Pharmacology

Background:

• Diabetic microvascular complications like retinopathy, nephropathy, and neuropathy affect many patients, even with good glycemic control.
• The polyol pathway, involving aldose reductase, is a potential contributor to these complications in animal models.
• Previous clinical trials of aldose reductase inhibitors have yielded disappointing results.

Purpose of the Study:

• To review the pathogenic mechanisms of the polyol pathway in diabetic complications.
• To summarize evidence linking the polyol pathway to microvascular diseases in diabetes.
• To discuss reasons for the failure of aldose reductase inhibitors in clinical trials.

Main Methods:

• Literature review of studies on the polyol pathway and diabetic complications.
• Analysis of evidence from animal studies and clinical trials.
• Discussion of potential therapeutic strategies involving aldose reductase inhibition.

Main Results:

• The polyol pathway, particularly aldose reductase activity, is strongly implicated in the pathogenesis of diabetic microvascular complications in preclinical studies.
• Despite this evidence, clinical trials of aldose reductase inhibitors have not demonstrated significant efficacy.
• Reasons for the discrepancy between animal data and clinical outcomes are discussed, including potential issues with drug development and trial design.

Conclusions:

• The polyol pathway remains a relevant target for understanding and potentially treating diabetic microvascular complications.
• Renewed efforts in developing effective aldose reductase inhibitors, possibly with improved strategies, are warranted.
• Further research is needed to elucidate the precise role of the polyol pathway and to overcome challenges in therapeutic development.